Hepatitis D cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatitis D}} | {{Hepatitis D}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Considering that patients who develop [[symptomatic]] [[hepatitis D]] may progress into [[liver failure]], adequate therapeutic regimen and research for new and more effective drugs, with less side-effects, and lower costs may be considered cost-effective. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hepatitis|D]] | [[Category:Hepatitis|D]] | ||
Line 14: | Line 12: | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 04:35, 11 August 2014
Hepatitis D |
Diagnosis |
Treatment |
Hepatitis D cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Hepatitis D cost-effectiveness of therapy |
Risk calculators and risk factors for Hepatitis D cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Considering that patients who develop symptomatic hepatitis D may progress into liver failure, adequate therapeutic regimen and research for new and more effective drugs, with less side-effects, and lower costs may be considered cost-effective.